Transarterial chemoembolization with pirarubicin-eluting microspheres in patients with unresectable hepatocellular carcinoma: Preliminary results

Mingjun Bai¹, Tao Pan¹, Churen Zhou¹, Ming-an Lì, Junwei Chen¹, Zhaolin Zeng¹, Duo Zhu¹, Chun Wu¹, Zaibo Jiang¹, Zhengran Li¹,*, Mingsheng Huang¹,*

¹ Department of Vascular Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Article info

Keywords:
Hepatocellular carcinoma
Therapeutic chemoembolization
Drug-eluting chemoembolization
Microspheres
Treatment outcome

Abstract

Purpose: To present the early results of pirarubicin-eluting microsphere transarterial chemoembolization (PE-TACE) for patients with unresectable hepatocellular carcinoma (HCC).

Materials and methods: We retrospectively analyzed 55 consecutive patients with HCC who received PE-TACE between April 1, 2015 and August 30, 2016. The complication rate, tumor response rate, progression-free survival (PFS), and overall survival (OS) were analyzed.

Results: Adverse events were generally mild and included abdominal pain and fever, although a major complication was reported in 1 patient (1.8%). During a median follow-up of 10.0 months (range, 3.0–24.0 months), 14 patients (25.5%) achieved a complete tumor response, 25 (45.5%) had a partial response, 9 (16.4%) showed stable disease, and 7 (12.7%) had disease progression. The 1-month overall response rate was 70.9%, and the local tumor response rate was 89.0%. The 1-month tumor response rate was 100% for Barcelona Clinic Liver Cancer (BCLC) stage A or B disease and 62.8% for BCLC stage C disease. The median PFS was 6.1 months (95% CI, 3.4–8.8 months; range, 1.0–24.0 months). The median OS was 11.0 months (95% CI, 7.1–14.9 months; range, 2.0–24.0 months). Kaplan-Meier analysis (log-rank test) found significant differences in OS between patients grouped by tumor number (P = 0.006), tumor size (P = 0.035), and Eastern Cooperative Oncology Group (ECOG) score (P = 0.005). The tumor number (1 vs. ≥2) was the only factor independently associated with OS (hazard ratio [HR], 2.867; 95% CI, 1.330–6.181; P = 0.007).

Conclusions: PE-TACE for unresectable HCC may be safe, with favorable tumor response rates and survival time, especially in patients with a single large tumor. Longer follow-up using a larger series is necessary to confirm these preliminary results.

Introduction

Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality, and one of the most common and lethal malignancies worldwide.² Over 700,000 new cases of HCC are diagnosed annually, many of which occur in China and other parts of the Asia-Pacific region.³–⁵ Only about 30% of patients with HCC are diagnosed at an early stage and can receive curative therapy such as surgical resection.³ For unresectable HCC, transcatheter arterial chemoembolization (TACE) is the current standard of care for patients with multinodular disease, as defined by the Barcelona Clinic Liver Cancer (BCLC) system.²,⁶–⁷ However, the median overall survival (OS) for patients with HCC treated with TACE is only 9–18 months,³,⁶,¹² highlighting the need for improvements in the techniques used to treat unresectable HCC.

Conventional TACE (cTACE) is performed by injecting a mixture of lipiodol and chemotherapeutic agent, such as doxorubicin, before using embolic materials to occlude the tumor-supplying arteries. Pirarubicin (tetrahydropyranoyl-adriamycin) is an antineoplastic cytotoxic agent...
that is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines. When used to treat hematologic malignancies, intravenous infusion of pirarubicin was associated with lower incidences of alopecia, gastrointestinal toxicities, and arrhythmia than doxorubicin-based chemotherapy regimens.

Drug-eluting chemoembolization (deTACE) has been developed to optimize TACE by increasing the concentration of chemotherapeutic drug in target lesions and allowing controlled drugrelease. According to previous studies comparing cTACE and deTACE, the peak plasma concentration (Cmax) and area under the plasma drug concentration–time curve (AUC) of doxorubicin were significantly lower for deTACE than for cTACE, indicating a favorable pharmacokinetic profile for deTACE. This was clinically reflected in the post-hoc analysis of the PRECISION V trial, which showed that deTACE (with doxorubicin) was associated with less liver, gastrointestinal, and cardiac toxicity than cTACE in patients with intermediate HCC. Several other clinical investigations have determined that deTACE can achieve a disease control rate of 79%–89% at 1 month post-therapy, and is associated with a low incidence of adverse events, most of which are mild in severity. Direct comparisons of deTACE and cTACE have reported either comparable outcomes or better outcomes for deTACE in terms of survival and tumor response. Furthermore, most studies have found that the safety profiles of deTACE and cTACE are broadly similar, although deTACE was associated with lower hepatotoxicity and fewer doxorubicin-related adverse effects, less post-procedural abdominal pain, and shorter hospital stays.

A variety of drug-eluting microspheres are available; however, most previous studies have focused on DC-Beads (Biocompatibles, Farnham, UK), whereas clinical investigations of HepaSphere (Merit Medical, South Jordan, UT, USA) are more limited. Notably, clinical data for the efficacy and safety of HepaSphere in Chinese patients with unresectable HCC are rare. In addition, no published studies have reported the use of pirarubicin-eluting microsphere TACE (PE-TACE) in patients with HCC, despite the evidence that pirarubicin may provide a better survival benefit than doxorubicin when used with cTACE.

Therefore, the aim of our study was to retrospectively assess the clinical outcomes and safety-related data in patients with unresectable HCC treated with PE-TACE using HepaSphere. The primary endpoints were tumor response and safety profile, and the secondary endpoints were OS and progression-free survival (PFS). In addition, the prognostic factor(s) for OS were evaluated.

Materials and methods

Patient selection

This retrospective study screened consecutive HCC patients treated with TACE in two hospitals (the Third Affiliated Hospital, Sun Yat-Sen University and Ling-nan Hospital, Sun Yat-Sen University) between April 1, 2015 and August 30, 2016. The study participants were enrolled according to predefined eligibility criteria. The institutional review board of Sun Yat-Sen University approved this study, and written informed consent was waived given the retrospective nature of the study.

The eligibility criteria were as follows: 1) HCC diagnosis confirmed by pathology or according to the current guidelines of the American Association for the Study of the Liver Diseases; 2) unresectable/non-ablatable HCC due to tumor burden or comorbidities; 3) treatment-naïve patient receiving PE-TACE as their initial therapy; 4) no extra-hepatic metastases; 5) Eastern Cooperative Oncology Group performance status (ECOG PS) 0–2; and 6) Child-Pugh class A or B cirrhosis. The exclusion criteria were as follows: 1) Tumor invasion of the main portal vein without collateral circulation around the occluded portal vein; 2) severe arteriovenous fistula; 3) platelet count <40,000/μL; and 4) international normalized ratio >1.5.

Treatment procedures

The TACE procedures were performed by two interventional oncologists (M.S.H. and Z.R.L.) with more than 10 years of experience in interventional techniques. Arteriography was performed under local anesthesia in order to identify the accessory arteries and then the TACE procedure was performed with a 5-F RH catheter (Cook Medical, Bloomington, IN, USA) super selectively in the tumor-feeding arteries using a microcatheter (Renegade, Boston Scientific, MA, USA; Progreat, Terumo, Tokyo, Japan) as described in our previous study.

The HepaSphere microspheres used in this study were loadable microspheres with a dry caliber of 30–60 μm that expanded to 120–240 μm after loading with pirarubicin. For drug loading, a 2.5 mg/mL solution of pirarubicin was prepared by adding 4 mL of normal saline to a vial containing 10 mg pirarubicin. The pirarubicin solution was loaded into the HepaSphere microspheres by mixing gently 5–10 times and then allowing the mixture to stand for 50 min. The median dosage of pirarubicin used in this study was 40 mg (range, 20–60 mg). After extraction of the supernatant, the pirarubicin-eluting HepaSphere microspheres were placed into a syringe, 20 mL of nonionic contrast medium (lipomide, Bayer, Leverkusen, Germany) was added, and the microspheres and contrast medium were mixed gently until homogeneity was achieved.

During TACE, the pirarubicin-loaded HepaSphere microspheres were injected slowly at a rate of 1 mL/min until stasis was observed. A waiting time of 5 min was used to allow the microspheres to redistribute in the feeding arteries. Angiography was performed to ensure complete devascularization of the feeding arteries, and additional microspheres were injected until stasis was achieved. If angiography revealed staining of the tumor after two vials of HepaSphere had been used, Embosphere microspheres (100–300 μm and 300–500 μm in diameter, Merit Medical Systems, South Jordan, UT, USA) were injected into the feeding arteries. Representative angiography images acquired during the injection of HepaSphere microspheres, and images showing the HepaSphere microspheres, are presented in Fig. 1.

Follow-up

The follow-up period was defined as the duration from the date of the initial treatment until death or the last visit, up to January 30, 2017. According to the standard follow-up protocol used in our centers, four-phase contrast-enhanced abdominal computed tomography or magnetic resonance images were obtained on the first, third, sixth, ninth, and twelfth month after PE-TACE for the first year and every 6 months thereafter. Repeated PE-TACE treatments were performed on demand for patients with viable tumors until TACE failure, as defined by the Liver Cancer Study Group of Japan, confirmed. No other chemotherapy regimens were used during the period of PE-TACE therapy. However, if TACE failure occurred, subsequent treatment included sorafenib or best supportive care based on the clinical judgment of our multidisciplinary teams. Antiviral therapy was routinely administered to patients with hepatitis virus infection.

Safety assessment

A primary outcome of our study was safety, which included treatment-related death, major complications, and minor complications. Treatment-related death was defined as death from any cause within 30 days of each PE-TACE treatment. Adverse events were classified using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Minor and major complications were defined in accordance with the Society of Interventional Radiology Classification System for Complications by Outcome: Minor complications were classified as grade A (no therapy, no consequence) or B (no therapy, no consequence, overnight admission for observation only), and major complications were classified as grade C (required therapy, minor hospitalization <48 h), D (required...
major therapy, unplanned increase in level of care, prolonged hospitalization, E (permanent adverse sequela), or F (death).

As an additional safety evaluation, the following laboratory investigations were performed (using venous blood samples) at baseline, 3 days post-TACE, and 30 days post-TACE: Albumin, alanine transaminase (ALT), aspartate transaminase (AST), cholinesterase (CHE), gamma-glutamyl transferase (GGT), platelet count (PLT), total bilirubin (TBIL), and white blood cell count (WBC).

Efficacy assessment

The efficacy outcomes measured were tumor response rates, PFS, and OS. The tumor response was evaluated 1, 3, and 6 months after the initial TACE using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria; the evaluation was performed independently by two experienced radiologists (G.S.H. and W.C.). Target and non-target lesions were defined in accordance with the mRECIST criteria. The tumor response at each time point was classified as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).

For the analysis, the tumor response in each patient was defined as the best tumor response of the three time points. The overall response (ORR) and disease control rate (DCR) were defined as CR + PR and CR + PR + SD, respectively. In addition, the serum alpha-fetoprotein (AFP) level was measured before (baseline) and 1 month after PE-TACE. The response to the date of tumor progression, death from any cause, or the last visit. The OS was defined as the time interval from the first PE-TACE to the date of death from any cause, or the last visit.

Study population

Among the 1470 patients screened, a total of 55 were included in the final analysis (Fig. 2). The demographic, clinical, and tumor characteristics of these 55 patients are summarized in Table 1. The study population was mostly male (85.5%), with a median age of 52.8 years (range, 32–86 years). The majority of the study participants had hepatitis B virus infection (89.1%) and were classified as ECOGPS 1 (56.4%) and Child-Pugh class A (83.6%). Twenty (36.4%) patients had 3 or more tumor lesions, 8 (14.5%) had 2 lesions, and 27 (49.1%) had only 1 lesion. The diameters of the largest tumor in each patient ranged from 8 to 160 mm, with a median size of 60.0 mm. The overall median follow-up was 24.0 months. A total of 94 sessions of PE-TACE were performed based on the tumor lesion type (target or non-target, as defined by the mRECIST criteria) and BCLC stage (A, B, or C). The cumulative PFS and OS were calculated using the Kaplan-Meier method, and compared between subgroups using the log-rank test. The factors associated with the PFS and OS were identified using univariate and multivariate Cox regression models. The following parameters were enrolled in the univariate analysis: Age (<55 years vs. ≥55 years), number of tumors (1 vs. ≥2), largest tumor diameter (<100 mm vs. ≥100 mm), ECOG score (0/1 vs. 2), BCLC stage (A/B vs. C), Child-Pugh class (A vs. B), macroscopic vascular invasion (yes vs. no), AFP level (<400 ng/mL vs. >400 ng/mL), and additional therapy with sorafenib (yes vs. no). Those parameters with \( P < 0.05 \) in the univariate analysis were included in the multivariate Cox regression analysis (using the enter method). The HRs and 95% CIs were calculated, and statistical significance was defined as \( P < 0.05 \).

Results

Statistical analysis

Data processing and statistical analyses were performed using SPSS 20.0 software (IBM Corp., Armonk, NY, USA). Quantitative variables were tested for normality and presented as the mean ± standard deviation and range if normally distributed or as median (range) if non-normally distributed. For tumor response, subgroup analyses were performed based on the tumor lesion type (target or non-target, as defined by the mRECIST criteria) and BCLC stage (A, B, or C). The cumulative PFS and OS were calculated using the Kaplan-Meier method, and compared between subgroups using the log-rank test. The factors associated with the PFS and OS were identified using univariate and multivariate Cox regression models. The following parameters were enrolled in the univariate analysis: Age (<55 years vs. ≥55 years), number of tumors (1 vs. ≥2), largest tumor diameter (<100 mm vs. ≥100 mm), ECOG score (0/1 vs. 2), BCLC stage (A/B vs. C), Child-Pugh class (A vs. B), macroscopic vascular invasion (yes vs. no), AFP level (<400 ng/mL vs. >400 ng/mL), and additional therapy with sorafenib (yes vs. no). Those parameters with \( P < 0.05 \) in the univariate analysis were included in the multivariate Cox regression analysis (using the enter method). The HRs and 95% CIs were calculated, and statistical significance was defined as \( P < 0.05 \).
Safety

The patients were hospitalized for an average of 3 days (range, 1–15 days) after PE-TACE. There were no procedure-related deaths within 1 month of PE-TACE. The complications observed after treatment are shown in Table 2. The only major complication was massive hydrothorax in one patient (1/55, 1.8%), but the symptoms subsided after percutaneous catheter drainage and albumin infusion. Post-embolization syndrome (PES) occurred as a minor complication in 80.0% of patients, and the symptoms included abdominal pain (70.9%), fever (32.7%), abdominal distention (7.3%), and nausea/vomiting (5.5%). However, if present, PES was mild in severity and self-limiting, without the requirement for any treatment.

Table 1
Baseline demographic and clinical characteristics of the study participants.

| Baseline characteristic | Value (n = 55) |
|------------------------|--------------|
| Age (years), mean ± standard deviation (range) | 52.8 ± 12.5 (32–86) |
| Sex (male/female) | 47/8 |
| Etiology (HBV/other) | 49/6 |
| Cirrhosis (yes/no) | 45/10 |
| BCLC stage (A/B/C) | 7/5/43 |
| Child-Pugh class (A/B) | 46/9 |
| ECQG PS score (0/1/2) | 17/31/7 |
| Largest tumor diameter (mm), median (range) | 60 (8–160) |
| Number of tumors (1/2/≥3) | 27/8/20 |
| Macroscopic vascular invasion (yes/no) | 29/26 |
| Ascites (yes/no) | 6/49 |
| Serum AFP level (<20 ng/mL/≥20 ng/mL) | 17/38 |
| HBV DNA level (<10⁶ IU/mL/≥10⁶ IU/mL) | 31/24 |
| Additional therapy (sorafenib/best supportive care) | 10/45 |

AFP: Alpha-fetoprotein, BCLC: Barcelona Clinic Liver Cancer, ECQG: Eastern Cooperative Oncology Group, HBV: Hepatitis B virus.

Table 2
Complications after treatment.

| Complication                  | No. | % |
|------------------------------|-----|---|
| Pain                         | 39  | 70.9 |
| Grade A                      | 28  | 50.9 |
| Grade B                      | 11  | 20.0 |
| Fever                        | 18  | 32.7 |
| Grade A                      | 15  | 27.2 |
| Grade B                      | 3   | 5.5 |
| Abdominal distention         | 4   | 7.3 |
| Grade A                      | 3   | 5.5 |
| Grade B                      | 1   | 1.8 |
| Nausea/vomiting              | 3   | 5.5 |
| Grade A                      | 1   | 1.8 |
| Grade B                      | 2   | 3.6 |
| Ascites                      | 4   | 7.3 |
| Grade A                      | 2   | 3.6 |
| Grade B                      | 2   | 3.6 |
| Hydrothorax                  | 1   | 1.8 |

Efficacy

Tumor response rates

Data for the overall and local tumor response rates at 1, 3, and 6 months after initial TACE are summarized in Tables 4 and 5. According to the mRECIST criteria, 14 (25.5%) patients achieved CR (Fig. 3), 25 (45.5%) patients showed PR, 9 (16.4%) patients had SD, and 7 (12.7%) patients had PD. At 1 month post-TACE, the ORR was 70.9%, the local tumor response in the target lesion was 89.1% (49/55), and the DCR was 87.3% (Table 4). The ORR and DCR were 60.4% and 66.0%, respectively, at 3 months post-TACE and 60.0% and 62.5%, respectively, at 6 months post-TACE (Table 5).

Sub-group analysis (Table 4) showed that the 1-month ORRs for BCLC were not elevated at 30 days post-TACE; indeed, the levels of the three enzymes at 30 days post-TACE were significantly lower than at baseline (P < 0.05), indicating resolution of any treatment-related hepatotoxicity.
ALT: Alanine transaminase, AST: Aspartate transaminase, CHE: Cholinesterase, GGT: Gamma-glutamyltransferase, PLT: Platelet count, TACE: Transcatheter arterial chemoembolization, TBIL: Total bilirubin, WBC: White blood cell count. The P values are for comparisons with the respective baseline value.

**Table 3**
Results of laboratory investigations.

| Variable              | Baseline (n = 55) | 3 days post-TACE (n = 55) | P       | 30 days post-TACE (n = 55) | P       |
|-----------------------|-------------------|---------------------------|---------|---------------------------|---------|
| ALT (U/L)             | 60.6 ± 109.7      | 344.5 ± 1121.5            | <0.001  | 45.7 ± 72.7               | 0.027   |
| AST (U/L)             | 55.6 ± 37.8       | 283.1 ± 368.5             | <0.001  | 46.3 ± 27.1               | 0.009   |
| Albumin (g/L)         | 38.1 ± 4.6        | 36.2 ± 4.7                | <0.001  | 37.3 ± 5.1                | 0.157   |
| TBIL (μmol/L)         | 27.6 ± 60.1       | 37.5 ± 58.7               | <0.001  | 29.1 ± 67.4               | 0.671   |
| GGT (g/L)             | 136.2 ± 124.7     | 141.3 ± 128.0             | <0.001  | 107.1 ± 75.8              | 0.009   |
| CHE (U/L)             | 5385.9 ± 2068.0   | 4722.6 ± 2142.3           | <0.001  | 4689.3 ± 2159.6           | 0.001   |
| PLT (× 10^9/L)        | 174.4 ± 103.3     | 153.0 ± 88.9              | <0.001  | 165.0 ± 105.2             | 0.391   |
| WBC (× 10^9/L)        | 6.5 ± 2.8         | 9.6 ± 6.0                 | <0.001  | 5.4 ± 2.3                 | <0.001  |

Data are presented as the mean ± standard deviation.

**Table 4**
Tumor response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.

| Overall tumor response | Target tumor response | Non-target tumor response | Newly developed tumor | BCLC stage A (n = 7) | BCLC stage B (n = 5) | BCLC stage C (n = 43) |
|------------------------|-----------------------|---------------------------|-----------------------|----------------------|---------------------|----------------------|
| CR                     | 14 (25.5%)            | 15 (27.3%)                | 2 (6.3%)              | 6 (85.7%)            | 0                   | 8 (18.6%)            |
| PR                     | 25 (45.5%)            | 34 (61.8%)                | 11 (34.4%)            | 1 (14.3%)            | 0                   | 5 (40.0%)            |
| SD                     | 9 (16.4%)             | 5 (9.1%)                  | 13 (40.6%)            | 0                    | 16 (100%)           | 14 (41.2%)           |
| PD                     | 7 (12.7%)             | 1 (1.8%)                  | 6 (18.7%)             | 4 (100%)             | 0                   | 7 (16.3%)            |
| ORR                    | 39 (70.9%)            | 49 (89.1%)                | 13 (40.6%)            | 7 (100%)             | 5 (100%)            | 27 (62.8%)           |
| DCR                    | 48 (87.3%)            | 54 (98.2%)                | 26 (81.3%)            | 7 (100%)             | 5 (100%)            | 36 (83.7%)           |

Data are presented as n (%). CR: Complete response, DCR: Disease control rate, ORR: Overall response rate, PD: Progressive disease, PR: Partial response, SD: Stable disease. The ORR was defined as CR + PR; DCR was defined as CR + PR + SD.

**Table 5**
Rates of overall tumor response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria at 1, 3, and 6 months after the first transcatheter arterial chemoembolization.

| Follow-up | CR      | PR      | SD      | PD      | ORR     | DCR     |
|-----------|---------|---------|---------|---------|---------|---------|
| 1 month (n = 55) | 9 (16.4%) | 30 (54.5%) | 9 (16.4%) | 7 (12.7%) | 39 (70.9%) | 48 (87.3%) |
| 3 months (n = 58) | 8 (15.1%) | 24 (45.3%) | 3 (5.7%) | 18 (34.0%) | 32 (60.4%) | 35 (66.0%) |
| 6 months (n = 60) | 12 (30.0%) | 12 (30.0%) | 1 (2.5%) | 15 (37.5%) | 24 (60.0%) | 25 (62.5%) |

Data are presented as n (%). CR: Complete response, DCR: Disease control rate, ORR: Overall response rate, PD: Progressive disease, PR: Partial response, SD: Stable disease. ORR was defined as CR + PR; DCR was defined as CR + PR + SD.

A total of 2 patients died before the 3-month follow-up.

A total of 15 patients died before the 6-month follow-up.

**APF level**

A total of 38 (69.1%) patients had APF-positive HCC (APF levels ≥20 ng/mL) and 17 (30.9%) had APF-negative HCC. Among the 38 APF-positive patients, 9 (23.7%) exhibited an increase in APF levels at 1 month post-TACE, whereas 29 (76.3%) showed a decrease in APF levels at 1 month post-TACE; in 5 of the 29 cases showing a decrease, APF fell to within the normal range. Two of the 17 patients with APF-negative HCC (11.8%) showed an elevation of APF to >20 ng/mL at 1 month post-TACE. The median APF values before and after PE-TACE were 268 ng/mL and 79 ng/mL, respectively, indicating a clinical response to PE-TACE (P < 0.05).

**Survival**

During the median follow-up period of 10.0 months (range, 3.0–24.0 months), 27 patients died and 15 patients survived; 25 patients died as a result of tumor progression, and the other 2 died of severe hepatic dysfunction. The median overall survival (OS) was 11.0 months (95%CI, 7.1–14.9 months; range, 2.0–24.0 months), with 6 months and 1 year OS rates of 75.0% and 53.1%, respectively (Fig. 4a). In univariate analysis, the tumor number (HR, 2.663; 95%CI, 1.269–5.588; P = 0.006), tumor size (HR, 1.465; 95%CI, 1.012–2.211; P = 0.035), and ECOG PS score (HR, 1.829; 95%CI, 1.158–2.888; P = 0.005) were significantly associated with OS (Table 6). However, in multivariate analysis, the tumor number (1 vs. ≥2; HR, 2.387; 95%CI, 1.330–6.181; P = 0.007) was the only factor significantly associated with OS (Table 6). Kaplan-Meier analysis (with the log-rank test) found significant differences in OS between patients grouped on the basis of tumor number (P = 0.010), tumor size (P = 0.035), and ECOG PS score (P = 0.010), but not those grouped by BCLC stage, Child-Pugh class, or presence/absence of macroscopic vascular invasion (Fig. 5).

The median PFS was 6.1 months (95%CI, 3.4–8.8 months; range, 1.0–24.0 months; Fig. 4b). In univariate analysis, the tumor size, tumor number, macroscopic vascular invasion, BCLC stage, and ECOG PS score were associated with PFS. In multivariate analysis, the tumor number (1 vs. ≥2; HR, 2.235; 95%CI, 1.173–4.259; P = 0.014), tumor size (<5 cm vs. ≥5 cm; HR, 2.375; 95%CI, 1.187–4.750; P = 0.014), and BCLC stage (A/B vs. C: HR, 7.406; 95%CI, 1.781–30.796; P = 0.006) were independently associated with PFS.

**Discussion**

To the best of our knowledge, this is the first study to use pirarubicin-eluting HepaSphere microspheres in the treatment of unresectable HCC...
by TACE. The tumor response rates obtained in our research suggest that PE-TACE may show clinical efficacy in patients with unresectable HCC. The 1-month ORR was 70.9% and the CR rate was 25.5%. Our results are comparable to those of previous studies using TACE with doxorubicin-eluting beads (DEB-TACE) to treat HCC, which reported ORR and CR rates as 51.6%–88.7% and 17.8–51.4%, respectively(25, 28, 38), despite differences between the studies in terms of the baseline characteristics of the study participants. Most previous investigations reporting a high tumor response rate included patients with early-or intermediate-stage HCC(28, 38). In our study, most of the enrolled patients (43/55, 78.2%) had advanced-stage HCC (BCLC stage C), and a notable finding of the subgroup analysis was that promising tumor response rates were observed in patients with BCLC stage C HCC: ACR rate of 18.6%, a PR rate of 44.2%, an ORR of 62.8%, and a DCR of 83.7%. For patients in our study with early-or intermediate-stage HCC (BCLC A or B), the CR rate was 50% and the 1-month ORR and DCR were both 100%. Although direct comparisons between studies should be made with caution, our tumor response rates are similar, if not higher, to those reported in 45 patients with BCLC stage A-B HCC treated with doxorubicin-loaded HepaSphere TACE (CR rate and ORR of 17.8% and 68.9%, respectively).15 Moreover, the 1-month target tumor response was as high as 89.1% in our study. One possible reason for the apparent higher tumor response in our study than in the report of Malagari et al.15 might be our use of pirarubicin rather than doxorubicin. Pirarubicin has been reported to have a greater cytotoxic effect than doxorubicin on HepG2 and Hu-H7 human hepatoma cell lines cultured in vitro.13 Furthermore, patients with HCC treated with
cTACE and pirarubicin had better survival than those treated with cTACE and doxorubicin (30). Another reason might be the use of an optimal microsphere size (120–240 μm) in our study, since the therapeutic action of drug-eluting microspheres seems to be related to microsphere diameter. Optimally sized microspheres might be able to penetrate better into the tumor vascular network and thereby exert a stronger

| Variable                  | n    | Univariate analysis | Multivariate analysis |
|---------------------------|------|---------------------|-----------------------|
|                          |      | HR 95%CI P          | HR 95%CI P            |
| Age                      |      |                     |                       |
| <55 years                 | 33   | 0.961 0.466–1.980   | 0.912                 |
| ≥55 years                 | 22   | 1                   |                       |
| Tumor number              |      |                     |                       |
| 1                         | 27   | 2.663 1.269–5.588   | 2.867 1.330–6.181     |
| ≥2                        | 28   | 1                   | 1                     |
| Tumor size                |      |                     |                       |
| <100 mm                   | 41   | 1.465 1.012–2.121   | 1.418 0.942–2.134     |
| ≥100 mm                   | 14   | 1                   | 1                     |
| ECOG score                |      |                     |                       |
| 0–1                       | 48   | 1.829 1.158–2.888   | 1.516 0.925–2.485     |
| 2                         | 7    | 1                   | 1                     |
| BCLC stage                |      |                     |                       |
| A–B                       | 12   | 2.741 0.829–9.067   | 0.80                   |
| C                         | 43   | 1                   |                       |
| Child-Pugh class          |      |                     |                       |
| A                         | 46   | 1.787 0.721–4.429   | 0.196                  |
| B                         | 9    | 1                   | 0.62                   |
| MVI                        |      |                     |                       |
| Absent                    | 26   | 2.003 0.940–4.267   | 0.352                  |
| Present                   | 29   | 1                   | 0.264                  |
| AFP level                 |      |                     |                       |
| ≤400 ng/mL                | 30   | 1.390 0.685–2.821   | 0.707–3.549           |
| >400 ng/mL                | 25   | 1                   | 0.264                  |
| Additional therapy with sorafenib |      |                     |                       |
| Yes                       | 10   | 1.584               |                       |
| No                        | 45   | 1                   |                       |

95%CI: 95% confidence interval, AFP:Alpha fetoprotein, BCLC: Barcelona Clinic Liver Cancer, ECOG: Eastern Cooperative Oncology Group, HR:Hazard ratio, MVI: Macroscopic vascular invasion.

Fig. 5. Kaplan-Meier analysis of factors affecting overall survival (OS). (a) Log-rank analysis of OS stratified according to tumor number (single vs. multiple, P = 0.006). (b) Log-rank analysis of OS stratified according to tumor size (<5 cm vs. 5–10 cm vs. ≥10 cm, P = 0.035). (c) Log-rank analysis of OS stratified according to ECOG score (0 vs. 1 vs. 2, P = 0.005). (d) Log-rank analysis of OS stratified according to BCLC stage (A/B vs. C, P = 0.080). (e) Log-rank analysis of OS stratified according to Child-Pugh class (A vs. B, P = 0.196). (f) Log-rank analysis of OS stratified according to macroscopic vascular invasion (absent vs. present, P = 0.062).
chemoembolization effect; hence, greater tumor necrosis might be achieved for microspheres 120–240 μm in size than for larger beads (≥300 μm).40 Indeed, a previous study found that DEB-TACE using microspheres of a 100–300 μm diameter was associated with a significantly higher survival rate and lower complication rate than DEB-TACE using larger beads (≤200 μm).41,42 A third reason for the good tumor response rates observed in our study may be the use of a high-quality PE-TACE procedure; a specialized team of experienced interventional radiologists performed all of our PE-TACE procedures using a standard protocol and super-selective technique. Furthermore, we injected the microspheres very slowly under free flow and used repeat angiography to confirm the embolization end-point. Overall, our preliminary results suggest that pirarubicin may be a promising chemotherapeutic agent for use in deTACE. Nonetheless, additional prospective studies directly comparing DEB-TACE and PE-TACE are needed.

Since most of our enrolled patients (78.2%) had advanced-stage HCC, we consider the median OS of 11.0 months and 1 year OS rate of 53.1% after PE-TACE to be satisfactory. Our results using PE-TACE are similar to those obtained using sorafenib (a standard therapeutic approach), which provides a median OS of 6.5–10.7 months and a 1 year OS rate of 30.0%–44.0%.41,43 If our findings are confirmed by additional clinical research, PE-TACE might be considered as an alternative or adjunct therapy to sorafenib since it is well tolerated and would not preclude the use of sorafenib; future randomized controlled trials are warranted to explore this possibility. The OS achieved in our study using PE-TACE to treat advanced-stage HCC was similar to, or perhaps better than, that reported in retrospective analyses of DEB-TACE.39,44 Baur et al. reviewed 14 patients with advanced-stage HCC treated with DEB-TACE and found the median OS to be 9.2 months.44 Furthermore, Gorodetski et al. analyzed data from 113 patients with advanced-stage HCC and portal vein thrombosis and calculated the median OS to be 5.0 months in those treated with c-TACE (n = 95) and 3.3 months in those treated with DEB-TACE (n = 38).39

Our data suggest that it may be feasible to use PE-TACE in the management of HCC to achieve good clinical outcomes. In our study, the most common cause of tumor progression and mortality was intrahepatic progression of daughter lesions rather than target tumor progression, as demonstrated by the local tumor response rate of the target lesions. On the one hand our results indicate good control of the target tumor, but on the other hand our data suggest that it may be difficult to control intrahepatic spread due to advanced tumor stage and poor liver function reserve. This highlights the importance of identifying and treating daughter lesions. Both the univariate and multivariate analyses found that the tumor number (1 versus ≥2) was significantly associated with OS, as previously established.44-47 The univariate analysis also identified tumor size and ECOG PS score as being associated with OS, consistent with existing publications.48-50 Taken together, our data imply that the best candidate for PE-TACE is a single and large HCC (>5 cm). In addition, some guidelines suggest that complete remission of a large tumor is hard to achieve using cTACE; thus, deTACE might be a good option for these patients.44,51 The effect of PE-TACE alone was limited in patients with multiple tumors, and further research is needed in order to explore whether the combination of PE-TACE with sorafenib or ablation could provide longer survival benefits than PE-TACE alone.

Our study also revealed that PE-TACE was well tolerated, and there were no treatment-related deaths, which is consistent with other studies of HepaSphere.(15, 17, 29). In the present series, there were no cases of cholecystitis, biliary damage, or abscess formation, which have been reported in previous series of deTACE.40 This may be due to differences in microsphere sizes and materials, since we have found no published studies reporting an association of HepaSphere with biliary damage. Future studies should focus on direct comparisons of safety and efficacy between different microspheres in order to determine the optimal microsphere for use in deTACE procedures. The only major complication in our study was massive hydrothorax in 1 (1.8%) case; we speculate that the massive hydrothorax might have been related to severe hypoalbuminemia after TACE and a poor baseline liver function (Child-Pugh class B8). The symptoms subsided after drainage of the hydrothorax, and the patient recovered; nonetheless, we suggest that close monitoring may be needed for patients with hypoalbuminemia who are treated with deTACE. There was no chemotherapy-related or systemic toxicity after PE-TACE in our study. The most common complication after PE-TACE was PES, which included abdominal pain (70.9%), fever (32.7%), and elevation of alanine transaminase/bilirubin (47.3%). These complications were all mild and self-limiting and did not require treatment. Furthermore, the incidence of minor complications in our study was similar to the value of 60%–80% that was previously reported in patients with advanced HCC receiving cTACE or DEB-TACE.43,48,49,52 However, some studies have observed a lower rate of minor complications (8.4%–18.0%) in patients treated with deTACE(25, 28, 38, 51); this apparent discrepancy may be due to the heavier tumor burden in most of our patients (a median tumor size of 6 cm, multiple tumors in 50.9% of patients, and macroscopic vascular invasion in 52.7%). There are a few potential limitations of our study. Firstly, this was a single-center, retrospective study that enrolled patients with different stages of HCC and with diverse baseline characteristics. Secondly, the sample size was small and the follow-up time was relatively short. Thus, our study maybe subject to selection and/or reporting bias, and longer follow-up on larger series is mandatory to confirm these preliminary results. Finally, our study lacked a control group, for example patients treated with c-TACE or sorafenib. Further research is needed to extend our observations.

Conclusions

Our findings provide preliminary evidence that PE-TACE may be a feasible and safe treatment for unresectable HCC that confers a good tumor response rate and long survival time, especially in patients with a single and large (>5 cm) HCC.

Author contribution

Ming-sheng Huang: Study supervision, Study concept and design, Administrative, technical, or material support.
Zheng-ran Li: Study concept and design.
Ming-jun Bai: Acquisition of data, Statistical analysis.
Tao Pan: Analysis and interpretation of data, Drafting of the manuscript, Statistical analysis.
Jun-wei Chen: Analysis and interpretation of data, Critical revision of the manuscript for intellectual content.
Chu-ren Zhou: Drafting of the manuscript, Critical revision of the manuscript for intellectual content.
Zhao-lin Zeng: Critical revision of the manuscript for intellectual content. Duo Zhu: Critical revision of the manuscript for intellectual content.
Chun Wu: Critical revision of the manuscript for intellectual content. Chu-ren Zhou: Critical revision of the manuscript for intellectual content.
Ming-an Li: Critical revision of the manuscript for intellectual content.
Zai-bo Jiang: Critical revision of the manuscript for intellectual content, Administrative, technical, or material support.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. Ca - Cancer J Clin. 2015;65(5):2015: 5-29.
2. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844-855.
3. Vemuri AP, Papanicolaou C, Furse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. The Oncologist. 2010; 15(Suppl 4):S5-13.
4. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835-853.
5. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4: 429-474.
